About us

Company Profile

 Ventaleon is developing inhaled treatments against viral infections. The Company’s lead therapy, is an inhaled LASAG (D,L-lysine acetylsalicylate • glycine), a lysin-salt formulation of well-known acetyl salicylic acid (Aspirin®), suitable as an ingredient for inhalable aerosol, has completed Phase II clinical trials to treat severe influenza.

 A proof-of-concept study in influenza patients with moderate to severe symptoms demonstrated more rapid symptom decline when administered via inhaled LASAG compared to standard of care. The Company is currently preparing to enter a pivotal clinical trial with inhaled LASAG. 

Ventaleon was founded as a spin-off from Activaero, a leading specialist in aerosol inhalation therapies and technologies, in 2012. Today, the company is supported by a group of leading international investors, including Coöperatief LSP U.A., BioMedInvest II LP, Abalis Finance AG, Vesalius Biocapital I S.A., Venture Incubator AG, CatheyWorldInvestment Ltd., and BayBg as well as Vectura plc., Dr. Scheuch and other private investors.